DE 110

Drug Profile

DE 110

Alternative Names: DE-110

Latest Information Update: 20 May 2017

Price : $50

At a glance

  • Originator Santen Pharmaceutical
  • Class Antiallergics; Eye disorder therapies
  • Mechanism of Action Glucocorticoid receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Allergic conjunctivitis; Conjunctivitis; Corneal disorders

Most Recent Events

  • 28 Jul 2015 No recent reports of development identified - Phase-I for Allergic conjunctivitis in USA (unspecified route)
  • 28 Jul 2015 No recent reports of development identified - Phase-II for Conjunctivitis in USA (Ophthalmic)
  • 28 Jul 2015 No recent reports of development identified - Phase-II for Corneal disorders in USA (Ophthalmic)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top